Discovery20

Latest Headlines

Trending stories — sign in for a personalized feed

Today

Elektros Inc.

As U.S. Markets Surge Like the Dot-Com Boom Era, ELEKTROS Inc. Celebrates a Powerful Rise in Global Momentum As Penny Stock and Microcap Investors Worldwide Continue Discovering the Company's Vision for Hard Rock Lithium Mining and EV Patent Technology

3 hours ago

Yesterday

Delivery Hero Se

Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer

a day ago

Grupa Kety Sa

Refers to Item 7 on the agenda: Report on the audit of the consolidated financial statements of Grupa Kęty SA

a day ago

Boc Hong Kong (holdings) Limited

The 4th BOCHK Science and Technology Innovation Prize Award Ceremony Concludes with Great Success

a day ago

Buffalo Potash Corporation

Buffalo Potash Files Annual Information Form and New Technical Report

2 days ago

Ionik Corporation

Ionik Announces 30-Day Extension of Senior Debt Facility

2 days ago

Galiano Gold, Inc.

Galiano Gold Announces Revisions to Omnibus Equity Incentive Plan

2 days ago

Yatra Online, Inc.

Yatra Online, Inc. Announces Results for the Three Months and Year Ended March 31, 2026

2 days ago

Uraniumx Discovery Corp.

UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change

2 days ago

Battery X Metals Inc.

Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet

2 days ago

Bolt Metals Corp.

Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec

2 days ago

F3 Uranium Corp

F3 Issues Common Shares for Interest Debt Settlement

2 days ago

Badlands Resources Inc

Badlands Announces Effective Date of Share Consolidation

2 days ago

May 22 2026

Pure Energy Minerals Ltd.

Pure Energy Minerals Announces Private Placement

2 days ago

Lir Life Sciences Corp.

LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories

2 days ago

Viasat, Inc.

Viasat Sets May 28, 2026 for Fourth Quarter and Fiscal Year 2026 Financial Results Conference Call and Webcast

2 days ago

Nuvve Holding Corp.

Nuvve Announces Receipt of Nasdaq Notice on Late Filing of Its Form 10-Q

2 days ago

Cytophage Technologies Ltd.

Cytophage Announces Filings Under the BIA

2 days ago

Molten Metals Corp.

Molten Metals Completes Airborne Geophysical Survey at Texas Project

2 days ago

Inspiration Mining Corp.

Inspiration Mining Arranges $600,000 Flow Through Financing

2 days ago

Published Oct 27 2025

5 min read

IMMUPHARMA ATTENDING BIO-EUROPE

Name: 6ix Investment Platform
Brand: 6ix

A logo for a company AI-generated content may be incorrect.

RNS REACH : 27 NOVEMBER 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

IMMUPHARMA ATTENDING BIO-EUROPE
3-5 November 2025, Vienna

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO will be attending the forthcoming Bio-Europe Conference in Vienna, from 3-5 November 2025.

BIO-Europe Vienna 2025, is the 31st annual premier biopharma partnering event. It brings together over 5,700 life science professionals from more than 3,000 companies across 60+ countries, facilitating more than 30,000 one-to-one meetings. This event makes it the leading life science partnering forum in Europe, fostering innovation, collaboration and growth in the biotech sector.

For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations	+44 (0) 207 206 2650 + 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson	+44 (0) 203 368 3550 +44 (0) 20 3650 3650 +44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk.

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.